Phosphocholine-binding antibody activities are hierarchically encoded in the sequence of the heavychain variable region: Dominance of self-association activity in the T15 idiotype

International Immunology

Volumn 25, Issue 6, 2013, Pages 345-352

  Srdic Rajic, Tatjana ^a   Kekovic, Goran ^b   Davidovic, Dragomir M ^b   Metlas, Radmila ^b  

^a National Cancer Research Center   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antibodies with autophilic properties; Informational spectrum method; Resonant recognition model; Superantibodies

Indexed keywords

HAPTEN; MUTANT PROTEIN; PARAPROTEIN; PEPTIDE DERIVATIVE; PHOSPHATE; PHOSPHORYLCHOLINE; PROTEIN ANTIBODY; T15 PROTEIN; T15 PROTEIN ATIBODY; UNCLASSIFIED DRUG; VH50 73 PEPTIDE;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; HEAVY CHAIN; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; SOMATIC MUTATION;

ANTIBODIES WITH AUTOPHILIC PROPERTIES; INFORMATIONAL SPECTRUM METHOD; RESONANT RECOGNITION MODEL; SUPERANTIBODIES;

ANIMALS; ANTIBODIES; BINDING SITES; IMMUNOGLOBULIN IDIOTYPES; IMMUNOGLOBULIN VARIABLE REGION; MICE; PHOSPHORYLCHOLINE;

EID: 84878452059     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxs156     Document Type: Article

References (37)

1. Tonegawa, S. 1983. Somatic generation of antibody diversity. Nature 302:575.
2. Shaw, P. X., Hörkkö, S., Chang, M. K. et al. 2000. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105:1731.
3. Chou, M. Y., Fogelstrand, L., Hartvigsen, K. et al. 2009. Oxidationspecific epitopes are dominant targets of innate natural antibodies in mice and humans. J. Clin. Invest. 119:1335.
4. Claflin, J. L. and Davie, J. M. 1974. Clonal nature of the immune response to phosphorylcholine. IV. Idiotypic uniformity of binding site-associated antigenic determinants among mouse antiphosphorylcholine antibodies. J. Exp. Med. 140:673.
5. Lee, W., Cosenza, H. and Köhler, H. 1974. Clonal restriction of the immune response to phosphorylcholine. Nature 247:55.
6. Cosenza, H. and Köhler, H. 1972. Specific inhibition of plaque formation to phosphorylcholine by antibody against antibody. Science 176:1027.
7. Köhler, H., Kaplan, D. R. and Strayer, D. S. 1974. Clonal depletion in neonatal tolerance. Science 186:643.
8. Crews, S., Griffin, J., Huang, H., Calame, K. and Hood, L. 1981. A single VH gene segment encodes the immune response to phosphorylcholine: somatic mutation is correlated with the class of the antibody. Cell 25:59.
9. Perlmutter, R. M., Crews, S. T., Douglas, R. et al. 1984. The generation of diversity in phosphorylcholine-binding antibodies. Adv. Immunol. 35:1.
10. Gearhart, P. J., Johnson, N. D., Douglas, R. and Hood, L. 1981. IgG antibodies to phosphorylcholine exhibit more diversity than their IgM counterparts. Nature 291:29.
11. Kenny, J. J., Moratz, C. M., Guelde, G. et al. 1992. Antigen binding and idiotype analysis of antibodies obtained after electroporation of heavy and light chain genes encoding phosphocholine-specific antibodies: a model for T15-idiotype dominance. J. Exp. Med. 176:1637.
12. Claflin, J. L., Hudak, S. and Maddalena, A. 1981. Antiphosphocholine hybridoma antibodies. I. Direct evidence for three distinct families in the murine response. J. Exp. Med. 153:352.
13. Clarke, S. H., Claflin, J. L., Potter, M. and Rudikoff, S. 1983. Polymorphism in anti-phosphocholine antibodies reflecting evolution of immunoglobulin families. J. Exp. Med. 157:98.
14. Claflin, J. L. and Berry, J. 1988. Genetics of the phosphocholinespecific antibody response to Streptococcus pneumoniae. Germline but not mutated T15 antibodies are dominantly selected. J. Immunol. 141:4012.
15. Perlmutter, R. M., Berson, B., Griffin, J. A. and Hood, L. 1985. Diversity in the germline antibody repertoire. Molecular evolution of the T15 VN gene family. J. Exp. Med. 162:1998.
16. Briles, D. E., Nahm, M., Schroer, K. et al. 1981. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J. Exp. Med. 153:694.
17. Malipiero, U. V., Levy, N. S. and Gearhart, P. J. 1987. Somatic mutation in anti-phosphorylcholine antibodies. Immunol. Rev. 96:59.
18. Chien, N. C., Pollock, R. R., Desaymard, C. and Scharff, M. D. 1988. Point mutations cause the somatic diversification of IgM and IgG2a antiphosphorylcholine antibodies. J. Exp. Med. 167:954.
19. Chen, C., Roberts, V. A. and Rittenberg, M. B. 1992. Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen. J. Exp. Med. 176:855.
20. Rudikoff, S., Giusti, A. M., Cook, W. D. and Scharff, M. D. 1982. Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. U.S.A. 79:1979.
21. Diamond, B. and Scharff, M. D. 1984. Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity. Proc. Natl. Acad. Sci. U.S.A. 81:5841.
22. Chang, S. P., Brown, M. and Rittenberg, M. B. 1982. Immunologic memory to phosphorylcholine. II. PC-KLH induces two antibody populations that dominate different isotypes. J. Immunol. 128:702.
23. Brown, M., Schumacher, M. A., Wiens, G. D., Brennan, R. G. and Rittenberg, M. B. 2000. The structural basis of repertoire shift in an immune response to phosphocholine. J. Exp. Med. 191:2101.
24. Chen, C., Roberts, V. A., Stevens, S., Brown, M., Stenzel-Poore, M. P. and Rittenberg, M. B. 1995. Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. EMBO J. 14:2784.
25. Veljkovic, V. and Slavic, M. 1972. Simple general-model of pseudopotentials. Phys. Rev. Lett. 29:105.
26. Veljković, V. and Cosić, I. 1987. A novel method of protein analysis for prediction of biological function: application to tumor toxins. Cancer Biochem. Biophys. 9:139.
27. Veljković, V. and Metlas, R. 1988. Identification of nanopeptide from HTLV-III, ARV-2 and LAVBRU envelope gp120 determining binding to T4 cell surface protein. Cancer Biochem. Biophys. 10:91.
28. Cosiæ, I. 1997. The Resonant Recognition Model of Macromolecular Bioactivity. Birkhäuser Verlag, Basel.
29. Cosiæ, I. and Pirogova, E. 2007. Bioactive peptide design using the Resonant Recognition Model. Nonlinear Biomed. Phys. 1:7.
30. Kang, C. Y. and Kohler, H. 1986. Immunoglobulin with complementary paratope and idiotope. J. Exp. Med. 163:787.
31. Kang, C. Y., Brunck, T. K., Kieber-Emmons, T., Blalock, J. E. and Kohler, H. 1988. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science 240:1034.
32. Zhao, Y., Russ, M., Morgan, C., Muller, S. and Kohler, H. 2005. Therapeutic applications of superantibodies. Drug Discov. Today 10:1231.
33. Rudikoff, S. and Potter, M. 1976. Size differences among immunoglobulin heavy chains from phosphorylcholine-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 73:2109.
34. Brown, M., Wiens, G. D., O'Hare, T., Stenzel-Poore, M. P. and Rittenberg, M. B. 1999. Replacements in the exposed loop of the T15 antibody VH CDR2 affect carrier recognition of PC-containing pathogens. Mol. Immunol. 36:205.
35. Goetze, A. M. and Richards, J. H. 1977. Structure-function relations in phosphorylcholine-binding mouse myeloma proteins. Proc. Natl. Acad. Sci. U.S.A. 74:2109.
36. Kaveri, S. V., Halpern, R., Kang, C. Y. and Köhler, H. 1991. Antibodies of different specificities are self-binding: implication for antibody diversity. Mol. Immunol. 28:773.
37. Potter, M. and Lieberman, R. 1970. Common individual antigenic determinants in five of eight BALB-c IgA myeloma proteins that bind phosphoryl choline. J. Exp. Med. 132:737.